English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5250239      線上人數 : 1211
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34107


    標題: Clinical burden of autosomal dominant polycystic kidney disease
    作者: Hung, Peir-Haur
    Lin, Chien-Hung
    Hung, Kuan-Yu
    Muo, Chih-Hsin
    Chung, Mu-Chi
    Chang, Chao-Hsiang
    Chung, Chi-Jung
    貢獻者: Ditmanson Med Fdn, Dept Internal Med, Chiayi Christian Hosp
    Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
    Taipei Vet Gen Hosp, Dept Pediat, Div Pediat Immunol & Nephrol
    Natl Yang Ming Univ, Inst Clin Med
    Taipei City Hosp, Dept Pediat, Zhongxing Branch
    Fu Jen Catholic Univ, Coll Sci & Engn
    Natl Taiwan Univ Hosp, Dept Internal Med
    China Med Univ Hosp, Management Off Hlth Data
    Taichung Vet Gen Hosp, Dept Med, Div Nephrol
    China Med Univ Hosp, Dept Urol
    China Med Univ Hosp, Dept Med Res
    China Med Univ, Dept Publ Hlth
    關鍵字: autosomal dominant polycystic kidney disease
    hemorrhagic stroke
    end-stage renal disease
    all-cause mortality
    time-dependent Cox proportional hazard regression
    日期: 2020
    上傳時間: 2022-11-18 11:24:12 (UTC+8)
    出版者: Impact Journals Llc
    摘要: There are no specific therapies for autosomal dominant polycystic kidney disease (ADPKD), and clinical data evaluating the effects of non-specific therapies on ADPKD patients are scarce. We therefore evaluated those effects using data from a longitudinal health insurance database collected from 2000-2010. We individually selected patients with and without ADPKD from inpatient data files as well as from the catastrophic illness registry in Taiwan based on 1:5 frequency matching for sex, age, and index year. The hazard ratios (HR) of all-cause mortality, ischemic stroke, hemorrhagic stroke and end-stage renal disease (ESRD) in ADPKD inpatients were elevated as compared to the controls. Similarly, ADPKD patients from the catastrophic illness registry had an increased risk of hemorrhagic stroke and ESRD. Allopurinol users also had an increased risk of all-cause mortality. The HR for developing ESRD after medication exposure was 0.47-fold for statin and 1.93-fold for pentoxifylline. These results reveal that patients with ADPKD (either inpatient or from the catastrophic illness registry) are at elevated risk for hemorrhagic stroke and ESRD, and suggest that allopurinol and pentoxifylline should not be prescribed to ADPKD patients due to possible adverse effects.
    關聯: Aging-Us, v.12, n.4, pp.12
    顯示於類別:[生活保健科技系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML563檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋